Combined positron emission and computed tomographies (PET/CT) using radio-ligands to the prostate membrane specific antigen (PSMA) is now a well-established tool for the staging of biochemically recurrent prostate cancer and is endorsed by both National Comprehensive Cancer Network (NCCN) guidelines and European Association of Urology Guidelines (EUA). The gene discussed is FOLH1; the disease is prostate cancer.